Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.

被引：0
|
作者：
Liao, Hao
Zhong, Jianxin
Pei, Wendi
Bin, Shao
Liu, Xiao-Ran
Rugo, Hope S.
Li, Huiping
机构：
[1] Peking Univ, Canc Hosp, Beijing, Peoples R China
[2] Peking Univ Third Hosp, Beijing, Peoples R China
[3] Beijing Canc Hosp, Beijing, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[5] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[6] Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[7] Peking Univ Canc Hosp & Inst, Dept Breast Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
535
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
    Giuliano, Mario
    Schettini, Francesco
    Rognoni, Carla
    Milani, Manuela
    Jerusalem, Guy
    Bachelot, Thomas
    De Laurentiis, Michelino
    Thomas, Guglielmo
    De Placido, Pietro
    Arpino, Grazia
    De Placido, Sabino
    Cristofanilli, Massimo
    Giordano, Antonio
    Puglisi, Fabio
    Pistilli, Barbara
    Prat, Aleix
    Del Mastro, Lucia
    Venturini, Sergio
    Generali, Daniele
    LANCET ONCOLOGY, 2019, 20 (10): : 1360 - 1369
  • [32] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Shimoi, Tatsunori
    Sagara, Yasuaki
    Hara, Fumikata
    Toyama, Tatsuya
    Iwata, Hiroji
    BREAST CANCER, 2020, 27 (03) : 340 - 346
  • [33] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Tatsunori Shimoi
    Yasuaki Sagara
    Fumikata Hara
    Tatsuya Toyama
    Hiroji Iwata
    Breast Cancer, 2020, 27 : 340 - 346
  • [34] Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer A network meta-analysis
    Jiang, Mengjie
    Chen, Wuzhen
    Hu, Yujie
    Chen, Chao
    Li, Huafeng
    MEDICINE, 2021, 100 (33)
  • [35] Adjuvant treatment in hormone receptor-positive early breast cancer: New approaches of endocrine therapy
    Nardin, Simone
    Ruelle, Tommaso
    Giannubilo, Irene
    Del Mastro, Lucia
    TUMORI JOURNAL, 2024, 110 (03): : 162 - 167
  • [36] Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis
    Chen, Juan
    Zhang, Xiaohui
    Lu, Yan
    Zhang, Ting
    Ouyang, Zhaolian
    Sun, Qiang
    BREAST CANCER, 2021, 28 (03) : 630 - 643
  • [37] Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis
    Juan Chen
    Xiaohui Zhang
    Yan Lu
    Ting Zhang
    Zhaolian Ouyang
    Qiang Sun
    Breast Cancer, 2021, 28 : 630 - 643
  • [38] Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
    Amir, Eitan
    Seruga, Bostjan
    Niraula, Saroj
    Carlsson, Lindsay
    Ocana, Alberto
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (17): : 1299 - 1309
  • [39] Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
    Brandao, Mariana
    Maurer, Christian
    Ziegelmann, Patricia Klarmann
    Ponde, Noam F.
    Ferreira, Arlindo
    Martel, Samuel
    Piccart, Martine
    de Azambuja, Evandro
    Debiasi, Marcio
    Lambertini, Matteo
    ESMO OPEN, 2020, 5 (04)
  • [40] Second-line Endocrine Therapy of Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis
    Wang, Tianzhuo
    Shen, Guoshuang
    Li, Jinming
    Huo, Xingfa
    Wang, Miaozhou
    Liu, Zhen
    Zhao, Fuxing
    Ren, Dengfeng
    Zhao, Jiuda
    CURRENT CANCER DRUG TARGETS, 2023, 23 (09) : 718 - 730
12345